Effects of congeners of amphetamine on the human heart.
Amphetamine
Congeners
Human heart
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
04
11
2023
accepted:
28
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
10
2
2024
Statut:
aheadofprint
Résumé
Central stimulatory and hallucinogenic drugs of abuse like amphetamine and most congeners of amphetamine can have cardiac harmful effects. These cardiac side effects can lead to morbidities and death. In this paper, we review current knowledge on the direct and indirect effects of these amphetamine congeners on the mammalian heart-more specifically, the isolated human heart muscle preparation. In detail, we address the question of whether and how these drugs affect cardiac contractility and their mechanisms of action. Based on this information, further research areas are defined, and further research efforts are proposed.
Identifiants
pubmed: 38340182
doi: 10.1007/s00210-024-02983-2
pii: 10.1007/s00210-024-02983-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Abbruscato TJ, Trippier PC (2018) DARK Classics in chemical neuroscience: methamphetamine. ACS Chem Neurosci. 9(10):2373–2378. https://doi.org/10.1021/acschemneuro.8b00123
doi: 10.1021/acschemneuro.8b00123
pubmed: 29602278
Adeoya-Osiguwa SA, Fraser LR (2005) Cathine and norephedrine, both phenylpropanolamines, accelerate capacitation and then inhibit spontaneous acrosome loss. Hum Reprod. 20(1):198–207. https://doi.org/10.1093/humrep/deh566
doi: 10.1093/humrep/deh566
pubmed: 15513978
Alsufyani HA, Docherty JR (2015) Direct and indirect cardiovascular actions of cathinone and MDMA in the anaesthetized rat. Eur J Pharmacol. 758:142–6. https://doi.org/10.1016/j.ejphar.2015.03.079
doi: 10.1016/j.ejphar.2015.03.079
pubmed: 25863258
Arch JR, Ainsworth AT, Cawthorne MA (1982) Thermogenic and anorectic effects of ephedrine and congeners in mice and rats. Life Sci. 30(21):1817–26. https://doi.org/10.1016/0024-3205(82)90319-8
doi: 10.1016/0024-3205(82)90319-8
pubmed: 7098772
Archer JR, Dargan PI, Hudson S, Wood DM (2013) Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. QJM. 106(2):147–52. https://doi.org/10.1093/qjmed/hcs219
doi: 10.1093/qjmed/hcs219
pubmed: 23178933
Aulakh CS, Mazzola-Pomietto P, Wozniak KM, Hill JL, Murphy DL (1994) Evidence that 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane-induced hypophagia and hyperthermia in rats is mediated by serotonin-2A receptors. J Pharmacol Exp Ther. 270(1):127–32
pubmed: 8035308
Balint EE, Falkay G, Balint GA (2009) Khat - a controversial plant. Wien Klin Wochenschr. 121(19–20):604–14. https://doi.org/10.1007/s00508-009-1259-7
doi: 10.1007/s00508-009-1259-7
pubmed: 19921126
Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 149(1–2):159–63. https://doi.org/10.1016/0014-2999(88)90056-8
doi: 10.1016/0014-2999(88)90056-8
pubmed: 2899513
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF et al (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203
doi: 10.1038/npp.2011.304
pubmed: 22169943
Beitter A (1901) Pharmkognostisch-chemische Untersuchung der Catha edulis. Archiv der Pharmazie 239:17–33
doi: 10.1002/ardp.19012390104
Bentur Y, Bloom-Krasik A, Raikhlin-Eisenkraft B (2008) Illicit cathinone (“Hagigat”) poisoning. Clin Toxicol (Phila). 46(3):206–10. https://doi.org/10.1080/15563650701517574
doi: 10.1080/15563650701517574
pubmed: 17852166
Bolli P (2008) Treatment resistant hypertension. Am J Ther. 15(4):351–5. https://doi.org/10.1097/MJT.0b013e318164c67b
doi: 10.1097/MJT.0b013e318164c67b
pubmed: 18645339
Boroda A, Akhter R (2008) Hallucinations in a child: a case demonstrating the pitfalls of urine dipstick drug testing. J Forensic Leg Med. 15(3):198–9. https://doi.org/10.1016/j.jflm.2007.07.003
doi: 10.1016/j.jflm.2007.07.003
pubmed: 18313019
Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT (2013) Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacol Toxicol 14:35. https://doi.org/10.1186/2050-6511-14-35
Brenneisen R, Geisshüsler S, Schorno X (1986) Metabolism of cathinone to (-)-norephedrine and (-)-norpseudoephedrine. J Pharm Pharmacol. 38(4):298–300. https://doi.org/10.1111/j.2042-7158.1986.tb04571.x
doi: 10.1111/j.2042-7158.1986.tb04571.x
pubmed: 2872296
Brenneisen R, Fisch HU, Koelbing U, Geisshüsler S, Kalix P (1990) Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol. 30(6):825–8. https://doi.org/10.1111/j.1365-2125.1990.tb05447.x
doi: 10.1111/j.1365-2125.1990.tb05447.x
pubmed: 2288828
pmcid: 1368302
Canal CE, Morgan D (2012) Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal. 4(7–8):556–76. https://doi.org/10.1002/dta.1333
doi: 10.1002/dta.1333
pubmed: 22517680
pmcid: 3722587
Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (2012) Toxicity of amphetamines: an update. Arch Toxicol. 86(8):1167–231. https://doi.org/10.1007/s00204-012-0815-5
doi: 10.1007/s00204-012-0815-5
pubmed: 22392347
Cassels BK, Sáez-Briones P (2018) Dark classics in chemical neuroscience: mescaline. ACS Chem Neurosci. 9(10):2448–2458. https://doi.org/10.1021/acschemneuro.8b00215
doi: 10.1021/acschemneuro.8b00215
pubmed: 29847089
Chaouche-Teyara K, Fournier B, Safar M, Dabiré H (1994) Systemic and regional haemodynamic effects of 1-(2,5-dimethoxy-4-iodo-phenyl)-2-aminopropane (DOI) and alpha-methyl-5-HT, in the anaesthetised rat. Clin Exp Hypertens. 16(6):779–98. https://doi.org/10.3109/10641969409078025
doi: 10.3109/10641969409078025
pubmed: 7858559
Cleary L, Buber R, Docherty JR (2002) Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur J Pharmacol. 451(3):303–308. https://doi.org/10.1016/s0014-2999(02)02305-1
doi: 10.1016/s0014-2999(02)02305-1
pubmed: 12242092
Cohen S (1975) Amphetamine abuse. JAMA. 231(4):414–5
doi: 10.1001/jama.1975.03240160076039
pubmed: 1172714
Coleman JA, Yang D, Zhao Z, Wen PC, Yoshioka C, Tajkhorshid E, Gouaux E (2019) Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. Nature. 569(7754):141–145. https://doi.org/10.1038/s41586-019-1135-1
doi: 10.1038/s41586-019-1135-1
pubmed: 31019304
pmcid: 6750207
Coutts RT, Malicky JL (1973) Synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). Can J Chem. 51:1402
doi: 10.1139/v73-210
Dedeoğlu A, Fisher LA (1991) Central and peripheral injections of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, modify cardiovascular function through different mechanisms. J Pharmacol Exp Ther. 259(3):1027–34
pubmed: 1762059
Derlet RW, Horowitz BZ (1995) Cardiotoxic drugs. Emerg Med Clin North Am. 13(4):771–91
doi: 10.1016/S0733-8627(20)30588-5
pubmed: 7588189
Docherty JR (2008) Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. 154(3):606–22. https://doi.org/10.1038/bjp.2008.124
doi: 10.1038/bjp.2008.124
pubmed: 18500382
pmcid: 2439527
Dominic P, Ahmad J, Awwab H, Bhuiyan MS, Kevil CG, Goeders NE, Murnane KS, Patterson JC, Sandau KE, Gopinathannair R, Olshansky B (2022) Stimulant drugs of abuse and cardiac arrhythmias. Circ Arrhythm Electrophysiol. 15(1):e010273. https://doi.org/10.1161/CIRCEP.121.010273
doi: 10.1161/CIRCEP.121.010273
pubmed: 34961335
Drew CD, Knight GT, Hughes DT, Bush M (1978) Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol. 6(3):221–5. https://doi.org/10.1111/j.1365-2125.1978.tb04588.x
doi: 10.1111/j.1365-2125.1978.tb04588.x
pubmed: 687500
pmcid: 1429447
Dunlap LE, Andrews AM, Olson DE (2018) Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem Neurosci. 9(10):2408–2427. https://doi.org/10.1021/acschemneuro.8b00155
doi: 10.1021/acschemneuro.8b00155
pubmed: 30001118
Edeleano L (1887) Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure. In: Berichte der Deutschen chemischen Gesellschaft zu Berlin; 20(1):616–622. https://doi.org/10.1002/cber.188702001142
Eirís-Puñal J, Fuentes-Pita P, Gómez-Lado C, Pérez-Gay L, López-Vázquez A, Quintas-Rey R, Barros-Angueira F, Pardo J (2020) Clinical and neurophysiological response to ephedrine in a patient affected with slow-channel congenital myasthenic syndrome. Rev Neurol 71(6):221–224. https://doi.org/10.33588/rn.7106.2020265 . Spanish, English
doi: 10.33588/rn.7106.2020265
pubmed: 32895905
Eliyahu U, Berlin S, Hadad E, Heled Y, Moran DS (2007) Psychostimulants and military operations. Mil Med. 172(4):383–7. https://doi.org/10.7205/milmed.172.4.383
doi: 10.7205/milmed.172.4.383
pubmed: 17484308
El-Menyar A, Mekkodathil A, Al-Thani H, Al-Motarreb A (2015) Khat use: history and heart failure. Oman Med J. 30(2):77–82. https://doi.org/10.5001/omj.2015.18
doi: 10.5001/omj.2015.18
pubmed: 25960830
pmcid: 4412450
Escobar JI, Karno M (1982) Chronic hallucinosis from nasal drops. JAMA. 247(13):1859–60
doi: 10.1001/jama.1982.03320380051028
pubmed: 6174744
Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 87:255–270. https://doi.org/10.1016/j.neubiorev.2018.02.001
doi: 10.1016/j.neubiorev.2018.02.001
pubmed: 29428394
pmcid: 8063758
FDA. “Phenylpropanolamine Advisory” (Press release). US Food and Drug Administration. 6 November 2000 https://web.archive.org/web/20100126085450/https:/www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052239.htm
Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 30(4):363–375. https://doi.org/10.1080/09540261.2018.1481827
doi: 10.1080/09540261.2018.1481827
pubmed: 30102081
Flanagan S, Minassian SL, Prokocimer P (2018) Pharmacokinetics of tedizolid and pseudoephedrine administered alone or in combination in healthy volunteers. J Clin Med. 7(6):150. https://doi.org/10.3390/jcm7060150
doi: 10.3390/jcm7060150
pubmed: 29899212
pmcid: 6025247
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 47:681–98. https://doi.org/10.1146/annurev.pharmtox.47.120505.105140
doi: 10.1146/annurev.pharmtox.47.120505.105140
pubmed: 17209801
Friebel H, Brilla R (1963) Über den zentralerregenden Wirkstoff der frischen Blätter und Zweigspitzen von Catha edulis Forskal. Naturwissenschaften 50:354–355. https://doi.org/10.1007/BF00629421
doi: 10.1007/BF00629421
Friström S, Airaksinen MM, Halmekoski J (1977) Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol (Copenh). 41(3):218–24. https://doi.org/10.1111/j.1600-0773.1977.tb02142.x
doi: 10.1111/j.1600-0773.1977.tb02142.x
pubmed: 578650
Gad MZ, Azab SS, Khattab AR, Farag MA (2021) Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts. Food Funct. 12(20):9563–9582. https://doi.org/10.1039/d1fo02093e
doi: 10.1039/d1fo02093e
pubmed: 34533553
Gergs U, Hofmann B, Neumann J (2024) Opposite effects of the hallucinogenic drugs DOI, DOM and mephedrone on force of contraction in human atrium. Naunyn-Schmiedeberg’s Arch Pharmacol (Abstract, in press)
Ghose K (1984) Tyramine pressor test: implications and limitations. Methods Find Exp Clin Pharmacol. 6(8):455–64
pubmed: 6492942
Głowacka K, Wiela-Hojeńska A (2021) Pseudoephedrine-benefits and risks. Int J Mol Sci. 22(10):5146. https://doi.org/10.3390/ijms22105146
doi: 10.3390/ijms22105146
pubmed: 34067981
pmcid: 8152226
Goodman and Gilman (2023) the pharmacological basis of therapeutics, 14th edn. Macmillan Publishing Co., London, England
Green JL, Wang GS, Reynolds KM, Banner W, Bond GR, Kauffman RE, Palmer RB, Paul IM, Dart RC (2017) Safety profile of cough and cold medication use in pediatrics. Pediatrics. 139(6):e20163070. https://doi.org/10.1542/peds.2016-3070
doi: 10.1542/peds.2016-3070
pubmed: 28562262
Gugelmann R, von Allmen M, Brenneisen R, Porzig H (1985) Quantitative differences in the pharmacological effects of (+)- and (-)-cathinone. Experientia. 41(12):1568–71. https://doi.org/10.1007/BF01964811
doi: 10.1007/BF01964811
pubmed: 4076402
Gumpper RH, Roth BL (2023) Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01567-7
doi: 10.1038/s41386-023-01567-7
pubmed: 36932180
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536
doi: 10.1124/jpet.111.184119
pubmed: 21810934
pmcid: 3200001
Hagel JM, Krizevski R, Kilpatrick K, Sitrit Y, Marsolais F, Lewinsohn E, Facchini PJ (2011) Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids. Genet Mol Biol. 34(4):640–6. https://doi.org/10.1590/S1415-47572011000400017
doi: 10.1590/S1415-47572011000400017
pubmed: 22215969
pmcid: 3229120
Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 61(3):364–81. https://doi.org/10.1016/j.neuropharm.2011.01.017
doi: 10.1016/j.neuropharm.2011.01.017
pubmed: 21256140
pmcid: 3110631
Haller CA, Jacob P 3rd, Benowitz NL (2002) Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther. 71(6):421–32. https://doi.org/10.1067/mcp.2002.124523
doi: 10.1067/mcp.2002.124523
pubmed: 12087345
Haller CA, Jacob P 3rd, Benowitz NL (2004) Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther. 75(4):259–73. https://doi.org/10.1016/j.clpt.2003.11.375
doi: 10.1016/j.clpt.2003.11.375
pubmed: 15060505
Haridy R (2023) Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 619(7969):227–228. https://doi.org/10.1038/d41586-023-02093-8
doi: 10.1038/d41586-023-02093-8
pubmed: 37386185
Hauner H, Hastreiter L, Werdier D, Chen-Stute A, Scholze J, Blüher M (2017) Efficacy and safety of cathine (nor-pseudoephedrine) in the treatment of obesity: a randomized dose-finding study. Obes Facts. 10(4):407–419. https://doi.org/10.1159/000478098
doi: 10.1159/000478098
pubmed: 28873376
pmcid: 5644935
Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol. 27(6):479–96. https://doi.org/10.1177/0269881113482532
doi: 10.1177/0269881113482532
pubmed: 23539642
pmcid: 3666194
Heffter A (1894) Ueber Pellote. In: Archiv für experimentelle Pathologie und Pharmakologie. 34, 65. https://doi.org/10.1007/bf01864855
Heijman J, Voigt N, Nattel S, Dobrev D (2014) Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 114(9):1483–1499. https://doi.org/10.1161/CIRCRESAHA.114.302226
Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK (2017) ADDUCE consortium. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 31(3):199–215. https://doi.org/10.1007/s40263-017-0410-7
doi: 10.1007/s40263-017-0410-7
pubmed: 28236285
pmcid: 5336546
Ho EL, Josephson SA, Lee HS, Smith WS (2009) Cerebrovascular complications of methamphetamine abuse. Neurocrit Care. 10(3):295–305. https://doi.org/10.1007/s12028-008-9177-5
doi: 10.1007/s12028-008-9177-5
pubmed: 19132558
Hoffmann L, Schumann N, Richter M (2018) Methamphetamine use in central Germany: a qualitative study on consumer groups and motives from the experts’ perspective. Psychother Psychosom Med Psychol 68(8):329–336. https://doi.org/10.1055/s-0043-118655
doi: 10.1055/s-0043-118655
pubmed: 28895615
Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45(3):462–471. https://doi.org/10.1038/s41386-019-0569-3
doi: 10.1038/s41386-019-0569-3
pubmed: 31733631
Huang J, Beng TH (1972) The pressor action of 2,5-dimethoxy-4-methylamphetamine in rats. J Pharm Pharmacol. 24(8):656–7. https://doi.org/10.1111/j.2042-7158.1972.tb09081.x
doi: 10.1111/j.2042-7158.1972.tb09081.x
pubmed: 4403750
Huang MC, Yang SY, Lin SK, Chen KY, Chen YY, Kuo CJ, Hung YN (2016) Risk of cardiovascular diseases and stroke events in methamphetamine users: a 10-year follow-up study. J Clin Psychiatry. 77(10):1396–1403. https://doi.org/10.4088/JCP.15m09872
doi: 10.4088/JCP.15m09872
pubmed: 27574836
Hull KM, Sanderson WD, Maher TJ (1993) Effect of phenylpropanolamine and related compounds on beta-adrenoceptor-induced activation of adenylyl cyclase. Life Sci. 52(15):1287–94
doi: 10.1016/S0024-3205(05)80018-9
pubmed: 8385253
Hußler W, Gergs U, Hoffmann B, Neumann J (2023) Human cardiac atrial effects of amphetamine and congeners. Naunyn-Schmiedeberg’s Arch Pharmacol 396(Suppl1):S44
Iepsen UW, Munch GW, Ryrsø CK, Secher NH, Lange P, Thaning P, Pedersen BK, Mortensen SP (2018) Muscle α-adrenergic responsiveness during exercise and ATP-induced vasodilation in chronic obstructive pulmonary disease patients. Am J Physiol Heart Circ Physiol. 314(2):H180–H187. https://doi.org/10.1152/ajpheart.00398.2017
doi: 10.1152/ajpheart.00398.2017
pubmed: 29030339
James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP et al (2011) Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 28:686–689
doi: 10.1136/emj.2010.096636
pubmed: 20798084
Jensen O, Rafehi M, Gebauer L, Brockmöller J (2021) Cellular uptake of psychostimulants - are high- and low-affinity organic cation transporters drug traffickers? Front Pharmacol. 11:609811. https://doi.org/10.3389/fphar.2020.609811
doi: 10.3389/fphar.2020.609811
pubmed: 33551812
pmcid: 7854383
Kahlig KM, Galli A (2003) Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol. 479(1–3):153–8. https://doi.org/10.1016/j.ejphar.2003.08.065
doi: 10.1016/j.ejphar.2003.08.065
pubmed: 14612146
Kalix P (1983) A comparison of the catecholamine releasing effect of the khat alkaloids (-)-cathinone and (+)-norpseudoephedrine. Drug Alcohol Depend. 11(3–4):395–401. https://doi.org/10.1016/0376-8716(83)90031-5
doi: 10.1016/0376-8716(83)90031-5
pubmed: 6617477
Kalix P (1984) Effect of the alkaloid (-)-cathinone on the release of radioactivity from rat striatal tissue prelabelled with 3H-serotonin. Neuropsychobiology. 12(2–3):127–9. https://doi.org/10.1159/000118124
doi: 10.1159/000118124
pubmed: 6527753
Kalix P (1992) Cathinone, a natural amphetamine. Pharmacol Toxicol. 70(2):77–86. https://doi.org/10.1111/j.1600-0773.1992.tb00434.x
doi: 10.1111/j.1600-0773.1992.tb00434.x
pubmed: 1508843
Kalix P (1996) Catha edulis, a plant that has amphetamine effects. Pharm World Sci. 18(2):69–73. https://doi.org/10.1007/BF00579708
doi: 10.1007/BF00579708
pubmed: 8739260
Kawasuji T, Koike K, Saito H (1996) Assessment of antihistaminic and antimuscarinic effects of optical isomers of ephedrine and methylephedrine by receptor binding assay in guinea pig ileal muscle. Biol Pharm Bull. 19(10):1307–10. https://doi.org/10.1248/bpb.19.1307
doi: 10.1248/bpb.19.1307
pubmed: 8913502
Kaye S, McKetin R, Duflou J, Darke S (2007) Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 102(8):1204–11. https://doi.org/10.1111/j.1360-0443.2007.01874.x
doi: 10.1111/j.1360-0443.2007.01874.x
pubmed: 17565561
Khoyi MA, Pousti A, Powis G, Zarrindast MR (1978) Tachyphylaxis to ethacrynic acid in the isolated atrium of guinea-pig and its relation to noradrenaline stores. Br J Pharmacol. 63(1):191–6. https://doi.org/10.1111/j.1476-5381.1978.tb07789.x
doi: 10.1111/j.1476-5381.1978.tb07789.x
pubmed: 647159
pmcid: 1668300
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y, Gando S (2003) The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg. 97(5):1239–1245. https://doi.org/10.1213/01.ANE.0000092917.96558.3C
doi: 10.1213/01.ANE.0000092917.96558.3C
pubmed: 14570629
Koczor CA, Ludlow I, Hight RS 2nd, Jiao Z, Fields E, Ludaway T, Russ R, Torres RA, Lewis W (2015) Ecstasy (MDMA) Alters cardiac gene expression and DNA methylation: implications for circadian rhythm dysfunction in the heart. Toxicol Sci. 148(1):183–91. https://doi.org/10.1093/toxsci/kfv170
doi: 10.1093/toxsci/kfv170
pubmed: 26251327
pmcid: 4731408
Koepsell H (2021) Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing. Expert Opin Drug Metab Toxicol. 17(6):635–653. https://doi.org/10.1080/17425255.2021.1915284
doi: 10.1080/17425255.2021.1915284
pubmed: 33896325
Kohli JD, Goldberg LI (1982) Cardiovascular effects of (–)-cathinone in the anaesthetized dog: comparison with (+)-amphetamine. J Pharm Pharmacol. 34(5):338–40. https://doi.org/10.1111/j.2042-7158.1982.tb04722.x
doi: 10.1111/j.2042-7158.1982.tb04722.x
pubmed: 6123578
Krasnova IN, Justinova Z, Cadet JL (2016) Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways. Psychopharmacology (Berl). 233(10):1945–62. https://doi.org/10.1007/s00213-016-4235-8
doi: 10.1007/s00213-016-4235-8
pubmed: 26873080
pmcid: 5627363
Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 63(3):585–640. https://doi.org/10.1124/pr.108.000869
doi: 10.1124/pr.108.000869
pubmed: 21752877
Krizevski R, Dudai N, Bar E, Lewinsohn E (2007) Developmental patterns of phenylpropylamino alkaloids accumulation in khat (Catha edulis, Forsk.). J Ethnopharmacol. 114(3):432–8. https://doi.org/10.1016/j.jep.2007.08.042
doi: 10.1016/j.jep.2007.08.042
pubmed: 17928181
Ladenburg A, Oelschlägel C (1889) Ueber das Pseudo-Ephedrin [On pseudo-ephedrine]. Berichte der Deutschen Chemischen Gesellschaft (in German) 22(2):1823–1827. https://doi.org/10.1002/cber.18890220225
doi: 10.1002/cber.18890220225
Lappin JM, Darke S, Farrell M (2017) Stroke and methamphetamine use in young adults: a review. J Neurol Neurosurg Psychiatry. 88(12):1079–1091. https://doi.org/10.1136/jnnp-2017-316071
doi: 10.1136/jnnp-2017-316071
pubmed: 28835475
Le Grand B, Talmant JM, Rieu JP, Patoiseau JF, Colpaert FC, John GW (1995) Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential. J Cardiovasc Pharmacol. 26(5):803–9. https://doi.org/10.1097/00005344-199511000-00018
doi: 10.1097/00005344-199511000-00018
pubmed: 8637196
Lee MR (2011) The history of Ephedra (ma-huang). J R Coll Physicians Edinb 41(1):78–84. https://doi.org/10.4997/JRCPE.2011.116
Lenhardt R, Kurz A, Sessler DI (1996) Thermoregulation and hyperthermia. Acta Anaesthesiol Scand Suppl. 109:34–8
pubmed: 8901936
Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, Mendelson J (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine: a doubleblind, placebo-controlled trial. Ann Intern Med. 133, 969–973. 10. 7326/0003-4819-133-12-2000012190-00012
Lewin L (1888) Ueber Anhalonium Lewinii. Archiv für Experimentelle Pathologie und Pharmakologie. 24:401–411. https://doi.org/10.1007/bf01923627
doi: 10.1007/bf01923627
Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01607-2
doi: 10.1038/s41386-023-01607-2
pubmed: 37258715
pmcid: 10584820
Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol. 14(3):269–74. https://doi.org/10.1177/026988110001400313
doi: 10.1177/026988110001400313
pubmed: 11106307
Liles JT, Dabisch PA, Hude KE, Pradhan L, Varner KJ, Porter JR, Hicks AR, Corll C, Baber SR, Kadowitz PJ (2006) Pressor responses to ephedrine are mediated by a direct mechanism in the rat. J Pharmacol Exp Ther. 316(1):95–105. https://doi.org/10.1124/jpet.105.090035
doi: 10.1124/jpet.105.090035
pubmed: 16002460
Liles JT, Baber SR, Deng W, Porter JR, Corll C, Murthy SN, Thomas SA, Kadowitz PJ (2007) Pressor responses to ephedrine are not impaired in dopamine beta-hydroxylase knockout mice. Br J Pharmacol. 150(1):29–36. https://doi.org/10.1038/sj.bjp.0706942
doi: 10.1038/sj.bjp.0706942
pubmed: 17099719
Lim SYM, Loo JSE, Alshagga M, Alshawsh MA, Ong CE, Pan Y (2022) Protein-ligand identification and in vitro inhibitory effects of cathine on 11 major human drug metabolizing cytochrome P450s. Int J Toxicol. 41(5):355–366. https://doi.org/10.1177/10915818221103790
doi: 10.1177/10915818221103790
pubmed: 35658727
pmcid: 9411691
Loi B, Corkery JM, Claridge H, Goodair C, Chiappini S, Gimeno Clemente C et al (2015) Deaths of individuals aged 16–24 years in the UK after using mephedrone. Hum Psychopharmacol 30:225–232
doi: 10.1002/hup.2423
pubmed: 26216555
López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol. 167(2):407–20. https://doi.org/10.1111/j.1476-5381.2012.01998.x
doi: 10.1111/j.1476-5381.2012.01998.x
pubmed: 22509960
pmcid: 3481047
Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 94(4):1085–1133. https://doi.org/10.1007/s00204-020-02693-7
doi: 10.1007/s00204-020-02693-7
pubmed: 32249347
pmcid: 7225206
Maitai CK (1981) Effect of cathinone on chick embryo heart. J Pharm Pharmacol. 33(3):195. https://doi.org/10.1111/j.2042-7158.1981.tb13755.x
doi: 10.1111/j.2042-7158.1981.tb13755.x
pubmed: 6116771
Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22:231–236
doi: 10.1016/j.euroneuro.2011.07.009
pubmed: 21824752
May SW, Phillips RS, Herman HH, Mueller PW (1982) Bioactivation of Catha edulis alkaloids: enzymatic ketonization of norpseudoephedrine. Biochem Biophys Res Commun. 104(1):38–44. https://doi.org/10.1016/0006-291x(82)91937-4
doi: 10.1016/0006-291x(82)91937-4
pubmed: 7073680
Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt NV, Mihovilovic MD, Baumann MH, Sitte HH (2016) Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters. Br J Pharmacol. 173(17):2657–68. https://doi.org/10.1111/bph.13547
doi: 10.1111/bph.13547
pubmed: 27391165
pmcid: 4978154
Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Hill JL, Murphy DL (1995) Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology (Berl). 117(2):193–9. https://doi.org/10.1007/BF02245187
doi: 10.1007/BF02245187
pubmed: 7753967
McCall RB, Harris LT (1988) 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur J Pharmacol. 151(1):113–6. https://doi.org/10.1016/0014-2999(88)90698-x
doi: 10.1016/0014-2999(88)90698-x
pubmed: 3416918
Mead J, Parrott A (2020) Mephedrone and MDMA: a comparative review. Brain Res. 1735:146740. https://doi.org/10.1016/j.brainres.2020.146740
doi: 10.1016/j.brainres.2020.146740
pubmed: 32087112
Merck Patentschrift and 274350 der Firma E. Merck in Darmstadt: Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl und Alkylendioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten. eingereicht am 24, 1912 Merck Patentschrift DE 274350 der Firma E. Merck in Darmstadt: Verfahren zur Darstellung von Alkyloxyaryl-, Dialkyloxyaryl und Alkylendioxyarylaminopropanen bzw. deren am Stickstoff monoalkylierten Derivaten. eingereicht am 24. Dezember 1912, erteilt am 16. Mai 1914
Meyer AC, Neugebauer NM, Zheng G, Crooks PA, Dwoskin LP, Bardo MT (2013) Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem. 127(2):187–98. https://doi.org/10.1111/jnc.12373
doi: 10.1111/jnc.12373
pubmed: 23875705
pmcid: 3795981
Meyer MR, Orschiedt T, Maurer HH (2013) Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 217(2):137–42. https://doi.org/10.1016/j.toxlet.2012.12.012
doi: 10.1016/j.toxlet.2012.12.012
pubmed: 23273999
Miller SC (2004) Safety concerns regarding ephedrine-type alkaloid-containing dietary supplements. Mil Med. 169(2):87–93. https://doi.org/10.7205/milmed.169.2.87
doi: 10.7205/milmed.169.2.87
pubmed: 15040625
Miura K (1887) Vorläufige Mitteilung über Ephedrin, ein neues Mydriaticum. Berl Klin Wochenschr 24:907–11
Morelli M, Tognotti E (2021) Brief history of the medical and non-medical use of amphetamine-like psychostimulants. Exp Neurol. 342:113754. https://doi.org/10.1016/j.expneurol.2021.113754
doi: 10.1016/j.expneurol.2021.113754
pubmed: 34000249
Morris JS, Groves RA, Hagel JM, Facchini PJ (2018) An N-methyltransferase from Ephedra sinica catalyzing the formation of ephedrine and pseudoephedrine enables microbial phenylalkylamine production. J Biol Chem. 293(35):13364–13376. https://doi.org/10.1074/jbc.RA118.004067
doi: 10.1074/jbc.RA118.004067
pubmed: 29929980
pmcid: 6120201
Moya-Huff FA, Maher TJ (1987) Adrenergic receptor subtype activation by (+)-, (-)- and (+/-)-norephedrine in the pithed rat. J Pharm Pharmacol. 39(2):108–12. https://doi.org/10.1111/j.2042-7158.1987.tb06954.x
doi: 10.1111/j.2042-7158.1987.tb06954.x
pubmed: 2881994
Moya-Huff FA, Kiritsy PJ, Maher TJ (1987) Cardiovascular differences between phenylpropanolamine and its related norephedrine isomers in the rat. J Pharm Sci. 76(2):114–6. https://doi.org/10.1002/jps.2600760206
doi: 10.1002/jps.2600760206
pubmed: 3572747
Nagai N (1897) Kanyaku maō seibun kenkyū seiseki (zoku). In: Yakugaku Zasshi, 13, p 901
Nencini P, Amiconi G, Befani O, Abdullahi MA, Anania MC (1984) Possible involvement of amine oxidase inhibition in the sympathetic activation induced by khat (Catha edulis) chewing in humans. J Ethnopharmacol. 11(1):79–86. https://doi.org/10.1016/0378-8741(84)90097-7
doi: 10.1016/0378-8741(84)90097-7
pubmed: 6147440
Nencini P, Fraioli S, Perrella D (1996) Tolerance does not develop to the suppressant effects of (-)-norpseudoephedrine on ingestive behavior in the rat. Pharmacol Biochem Behav. 53(2):297–301. https://doi.org/10.1016/0091-3057(95)02024-1
doi: 10.1016/0091-3057(95)02024-1
pubmed: 8808135
Neumann J (2006) The cardiac β-adrenoceptors: where and why? Cardiovasc Res. 71(1):6–7
doi: 10.1016/j.cardiores.2006.05.007
pubmed: 16716280
Neumann J, Hofmann B, Dhein S, Gergs U (2023a) Cardiac roles of serotonin (5-HT) and 5-HT-receptors in health and disease. Int J Mol Sci 24(5):4765. https://doi.org/10.3390/ijms24054765
Neumann J, Hußler W, Hofmann B, Gergs U (2023b) Methamphetamine increases force of contraction in isolated human atrial preparations by releasing noradrenaline. Toxicol Lett. 383:112–120. https://doi.org/10.1016/j.toxlet.2023.06.012
doi: 10.1016/j.toxlet.2023.06.012
pubmed: 37394154
Neumann J, Hofmann B, Gergs U (2017) Production and function of serotonin in cardiac cells. “Serotonin - A Chemical Messenger Between All Types of Living Cells”, Chapter 13; 271-305 ISBN 978-953-51-3361-2 Kaneez Fatima Shad (ed.)
Neumann J, Azatsian K, Höhm C, Hofmann B, Gergs U (2023c) Cardiac effects of ephedrine, norephedrine, mescaline and 3,4-methylenedioxymethamphetamine (MDMA) in mouse and human atrial preparations. Naunyn Schmiedeberg´s Arch Pharmacol 396:275–287. https://doi.org/10.1007/s00210-022-02315-2
Neumann J, Hußler W, Hofmann B, Gergs U (2023d) Cardiac effects of amphetamine, pseudoephedrine, norpseudoephedrine (cathine) or cathinone in atrium from mice and in human atrial preparations. J Cardiovasc Pharmacol. https://doi.org/10.1097/FJC.0000000000001536
Ngan Kee WD, Khaw KS (2006) Vasopressors in obstetrics: what should we be using? Curr Opin Anaesthesiol. 19(3):238–43. https://doi.org/10.1097/01.aco.0000192816.22989.ba
doi: 10.1097/01.aco.0000192816.22989.ba
pubmed: 16735804
Ohler N (2016) Der Totale Rausch” Toxic. The secret weapon of the reich. Drugs in Nazi Germany. Verlag Kiepenheuer & Witsch, Colonia, Germany (ISBN 978-3-462-04733-2)
Orzechowski RF, Goldstein FJ (1973) Species variation in blood pressure responses to mescaline: evidence of histamine release. Toxicol Appl Pharmacol. 25(4):525–33. https://doi.org/10.1016/0041-008x(73)90021-5
doi: 10.1016/0041-008x(73)90021-5
pubmed: 4126341
Papaseit E, Olesti E, de la Torre R, Torrens M, Farre M (2017) Mephedrone concentrations in cases of clinical intoxication. Curr Pharm Des. 23(36):5511–5522. https://doi.org/10.2174/1381612823666170704130213
doi: 10.2174/1381612823666170704130213
pubmed: 28677506
Philogene-Khalid HL, Hicks C, Reitz AB, Liu-Chen LY, Rawls SM (2017) Synthetic cathinones and stereochemistry: S-enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats. Drug Alcohol Depend. 178:119–125. https://doi.org/10.1016/j.drugalcdep.2017.04.024
doi: 10.1016/j.drugalcdep.2017.04.024
pubmed: 28646714
pmcid: 5548612
Pitts EG, Curry DW, Hampshire KN, Young MB, Howell LL (2018) (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. Psychopharmacology (Berl). 235(2):377–392. https://doi.org/10.1007/s00213-017-4812-5
doi: 10.1007/s00213-017-4812-5
pubmed: 29248945
Rätsch C (2018) Enzyklopädie der psychoaktiven Pflanzen: Botanik, Ethnopharmakologie und Anwendung. Das Standardwerk zu psychoaktiven Pflanzen, 2nd edn. AT Verlag, Aarau, Switzerland
Ray TS (2010) Psychedelics and the human receptorome. PLoS One. 5(2):e9019. https://doi.org/10.1371/journal.pone.0009019
doi: 10.1371/journal.pone.0009019
pubmed: 20126400
pmcid: 2814854
Regan L, Mitchelson M, Macdonald C (2011) Mephedrone toxicity in a Scottish emergency department. Emerg Med J. 28(12):1055–8. https://doi.org/10.1136/emj.2010.103093
doi: 10.1136/emj.2010.103093
pubmed: 21183522
Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 26(8):1327–37. https://doi.org/10.1016/j.euroneuro.2016.05.001
doi: 10.1016/j.euroneuro.2016.05.001
pubmed: 27216487
Rieger G. Paranoid-halluzinatorische Psychosen nach Einnahme von D-Nor-pseudoephedrinhaltigen Appetitzüglern. Kasuistische Mitteilung [Paranoid hallucinatory psychosis following medication with anorectics containing D-nor-pseudoephedrin. Case report (author’s transl)]. Nervenarzt. 1981;52(7):423-5. German
Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther. 307(1):138–45. https://doi.org/10.1124/jpet.103.053975
doi: 10.1124/jpet.103.053975
pubmed: 12954796
Ryan DH (1996) Medicating the obese patient. Endocrinol Metab Clin North Am. 25(4):989–1004. https://doi.org/10.1016/s0889-8529(05)70366-2
doi: 10.1016/s0889-8529(05)70366-2
pubmed: 8977057
Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl). 98(4):495–9. https://doi.org/10.1007/BF00441948
doi: 10.1007/BF00441948
pubmed: 2505289
Sanchez S (1929) Sur un homologue de l’ephedrine. Bull Soc Chim Fr 45:284–286
Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther. 246(3):924–8
pubmed: 2843634
Sauder KL, Brady WJ Jr, Hennes H (1997) Visual hallucinations in a toddler: accidental ingestion of a sympathomimetic over-the-counter nasal decongestant. Am J Emerg Med. 15(5):521–6. https://doi.org/10.1016/s0735-6757(97)90200-x
doi: 10.1016/s0735-6757(97)90200-x
pubmed: 9270396
Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA (2003) Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 49(1):121–32. https://doi.org/10.1373/49.1.121
doi: 10.1373/49.1.121
pubmed: 12507968
Shaerzadeh F, Streit WJ, Heysieattalab S, Khoshbouei H (2018) Methamphetamine neurotoxicity, microglia, and neuroinflammation. J Neuroinflammation. 15(1):341. https://doi.org/10.1186/s12974-018-1385-0
doi: 10.1186/s12974-018-1385-0
pubmed: 30541633
pmcid: 6292109
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J (2003) Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 289(12):1537–45. https://doi.org/10.1001/jama.289.12.1537
doi: 10.1001/jama.289.12.1537
pubmed: 12672771
Shin HS (1997) Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 25(6):657–62
pubmed: 9193866
Shoptaw SJ, Kao U, Ling W (2009) Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009(1):003026. https://doi.org/10.1002/14651858.CD003026.pub3
doi: 10.1002/14651858.CD003026.pub3
Shufman NE, Witztum E, Vass A (1994) [Ephedrine psychosis]. Harefuah. 127(5-6):166-8, 215. Hebrew
Shulgin AT, Manning T, Daley PF (2011) The Shulgin Index: volume One, psychedelic phenethylamines and related compounds transform press, Berkeley, CA, USA
Siegl PK, Orzechowski RF (1977) Actions of mescaline on isolated rat atria. J Pharm Sci. 66(7):938–41. https://doi.org/10.1002/jps.2600660708
doi: 10.1002/jps.2600660708
pubmed: 18592
Silva B, Soares J, Rocha-Pereira C, Mladěnka P, Remião F (2022) On behalf of the oemonom researchers. Khat, a cultural chewing drug: a toxicokinetic and toxicodynamic summary. Toxins (Basel) 14(2):71. https://doi.org/10.3390/toxins14020071
Simmons SJ, Leyrer-Jackson JM, Oliver CF, Hicks C, Muschamp JW, Rawls SM, Olive MF (2018) DARK classics in chemical neuroscience: cathinone-derived psychostimulants. ACS Chem Neurosci. 9(10):2379–2394. https://doi.org/10.1021/acschemneuro.8b00147
doi: 10.1021/acschemneuro.8b00147
pubmed: 29714473
Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V (2018) Hallucinogen persisting perception disorder: a literature review and three case reports. J Addict Dis. 37(3–4):268–278. https://doi.org/10.1080/10550887.2019.1673655
doi: 10.1080/10550887.2019.1673655
pubmed: 31613183
Snyder SH, Faillace L, Hollister L (1968) 2,5-Dimethoxy-4-methylamphetamine: new hallucinogenic drug. Science. 159(3822):1492
doi: 10.1126/science.159.3822.1492.a
pubmed: 5732495
Sokolov BP, Polesskaya OO, Uhl GR (2003) Mouse brain gene expression changes after acute and chronic amphetamine. J Neurochem. 84(2):244–52. https://doi.org/10.1046/j.1471-4159.2003.01523.x
doi: 10.1046/j.1471-4159.2003.01523.x
pubmed: 12558987
Späth E (1919) Über die Anhalonium-Alkaloide: I. Anhalin und Mezcalin. In: Monatsh Chem 40, Nr. 2, S. 129–154. https://doi.org/10.1007/BF01524590
Spiller HA, Hays HL, Aleguas A Jr (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 27(7):531–43. https://doi.org/10.1007/s40263-013-0084-8
doi: 10.1007/s40263-013-0084-8
pubmed: 23757186
Steuer AE, Boxler MI, Stock L, Kraemer T (2016) Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 243:48–55. https://doi.org/10.1016/j.toxlet.2015.12.001
doi: 10.1016/j.toxlet.2015.12.001
pubmed: 26721607
Sugimoto K, Okamura K, Tanaka H, Takashima S, Ochi H, Yamamoto T, Matoba R (2009) Methamphetamine directly accelerates beating rate in cardiomyocytes by increasing Ca(2+) entry via L-type Ca(2+) channel. Biochem Biophys Res Commun. 390(4):1214–20. https://doi.org/10.1016/j.bbrc.2009.10.124
doi: 10.1016/j.bbrc.2009.10.124
pubmed: 19878660
Sullivan G (1996) Acute psychosis following intravenous abuse of pseudoephedrine: a case report. J Psychopharmacol. 10(4):324–5. https://doi.org/10.1177/026988119601000413
doi: 10.1177/026988119601000413
pubmed: 22302983
Tadepalli AS, Friedman E, Gershon S (1975) Cardiovascular actions of 2,5-dimethoxy-4-methylamphetamine (DOM) in the cat. Eur J Pharmacol. 31(2):305–12. https://doi.org/10.1016/0014-2999(75)90053-9
doi: 10.1016/0014-2999(75)90053-9
pubmed: 1056857
Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl). 94(2):213–6. https://doi.org/10.1007/BF00176847
doi: 10.1007/BF00176847
pubmed: 3127847
Toennes SW, Harder S, Schramm M, Niess C, Kauert GF (2003) Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br J Clin Pharmacol. 56(1):125–30. https://doi.org/10.1046/j.1365-2125.2003.01834.x
doi: 10.1046/j.1365-2125.2003.01834.x
pubmed: 12848785
pmcid: 1884326
Turdi S, Schamber RM, Roe ND, Chew HG Jr, Culver B, Ren J (2009) Acute methamphetamine exposure inhibits cardiac contractile function. Toxicol Lett. 189(2):152–8. https://doi.org/10.1016/j.toxlet.2009.05.015
doi: 10.1016/j.toxlet.2009.05.015
pubmed: 19481142
pmcid: 2730117
Uekusa K, Hayashida M, Saito N, Mashiko K, Hara K, Waters B, Ohno Y (2013) Methamphetamine and amphetamine concentrations in survivors of body-packer syndrome in Japan. Forensic Sci Int. 227(1–3):45–7. https://doi.org/10.1016/j.forsciint.2012.10.005
doi: 10.1016/j.forsciint.2012.10.005
pubmed: 23116635
Ulus IH, Maher TJ, Wurtman RJ (2000) Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 59(12):1611–21. https://doi.org/10.1016/s0006-2952(00)00306-3
doi: 10.1016/s0006-2952(00)00306-3
pubmed: 10799660
Urabe M (1982) Inhibitory mechanism of methamphetamine in the isolated myocardium of bullfrog. Arch Internationales de Pharmacodynamie et de Therapie. 257(2):239–254
Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ (2023) Mescaline: The forgotten psychedelic. Neuropharmacology. 222:109294. https://doi.org/10.1016/j.neuropharm.2022.109294
doi: 10.1016/j.neuropharm.2022.109294
pubmed: 36252614
Vanakoski J, Strömberg C, Seppälä T (1993) Effects of a sauna on the pharmacokinetics and pharmacodynamics of midazolam and ephedrine in healthy young women. Eur J Clin Pharmacol. 45(4):377–81. https://doi.org/10.1007/BF00265959
doi: 10.1007/BF00265959
pubmed: 8299674
Vansal SS, Feller DR (1999) Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol. 58(5):807–10. https://doi.org/10.1016/s0006-2952(99)00152-5
doi: 10.1016/s0006-2952(99)00152-5
pubmed: 10449190
Varner KJ, Diagle K, Weed PF, Lewis PB, Mahne SE, Sankaranarayanan A, Winsauer PJ (2013) Comparison of the behavioural and cardiovascular effects of mephedrone with other drug of abuse in rats. Psychopharmacology 225:675–685. https://doi.org/10.1007/s00213-012-2855-1
doi: 10.1007/s00213-012-2855-1
pubmed: 22972412
Verheijen JC, Wiig KA, Du S, Connors SL, Martin AN, Ferreira JP, Slepnev VI, Kochendörfer U (2009) Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition. Bioorg Med Chem Lett. 19(12):3243–6. https://doi.org/10.1016/j.bmcl.2009.04.089
doi: 10.1016/j.bmcl.2009.04.089
pubmed: 19423342
Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology. 19(4):241–51. https://doi.org/10.1016/S0893-133X(98)00013-X
doi: 10.1016/S0893-133X(98)00013-X
pubmed: 9718588
Watson R, Woodman R, Lockette W (2010) Ephedra alkaloids inhibit platelet aggregation. Blood Coagul Fibrinolysis. 21(3):266–71. https://doi.org/10.1097/MBC.0b013e328337b39f
doi: 10.1097/MBC.0b013e328337b39f
pubmed: 20179577
Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU (1994) Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther. 55(5):556–62. https://doi.org/10.1038/clpt.1994.69
doi: 10.1038/clpt.1994.69
pubmed: 7910126
Wijetunga M, Seto T, Lindsay J, Schatz I (2003) Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol. 41(7):981–6. https://doi.org/10.1081/clt-120026521
doi: 10.1081/clt-120026521
pubmed: 14705845
Wolfes O (1930) Über das Vorkommen von D-nor-iso-Ephedrin in Catha edulis. Arch Pharm (Weinheim) 286, 81-83
Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, Ramsey J, Lee T, Holt DW, Dargan PI (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol. 6(3):327–30. https://doi.org/10.1007/s13181-010-0018-5
doi: 10.1007/s13181-010-0018-5
pubmed: 20358417
pmcid: 3550484
Wood DM, Greene SL, Dargan PI (2011) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 28:280–282
doi: 10.1136/emj.2010.092288
pubmed: 20581379
Wood GC, Boucher AB, Johnson JL, Wisniewski JN, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, Fabian TC (2014) Effectiveness of pseudoephedrine as adjunctive therapy for neurogenic shock after acute spinal cord injury: a case series. Pharmacotherapy. 34(1):89–93. https://doi.org/10.1002/phar.1335
doi: 10.1002/phar.1335
pubmed: 23918202
World Anti-Doping Agency (WADA). The World Anti-Doping Code, Prohibited List 2021. https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf
World Health Organization. World Health Organization model list of essential medicines: 21
Xu S, Mao M, Zhang S, Qian R, Shen X, Shen J, Wang X (2019) A randomized double-blind study comparing prophylactic norepinephrine and ephedrine infusion for preventing maternal spinal hypotension during elective cesarean section under spinal anesthesia: A CONSORT-compliant article. Medicine (Baltimore). 98(51):e18311. https://doi.org/10.1097/MD.0000000000018311
doi: 10.1097/MD.0000000000018311
pubmed: 31860981
pmcid: 6940128
Yamamoto H, Imai K, Takamatsu Y, Kamegaya E, Kishida M, Hagino Y, Hara Y, Shimada K, Yamamoto T, Sora I, Koga H, Ikeda K (2005) Methamphetamine modulation of gene expression in the brain: analysis using customized cDNA microarray system with the mouse homologues of KIAA genes. Brain Res Mol Brain Res. 137(1–2):40–6. https://doi.org/10.1016/j.molbrainres.2005.02.028
doi: 10.1016/j.molbrainres.2005.02.028
pubmed: 15950759
Yang X, Wang Y, Li Q, Zhong Y, Chen L, Du Y, He J, Liao L, Xiong K, Yi CX, Yan J (2018) The main molecular mechanisms underlying methamphetamine-induced neurotoxicity and implications for pharmacological treatment. Front Mol Neurosci. 11:186. https://doi.org/10.3389/fnmol.2018.00186
doi: 10.3389/fnmol.2018.00186
pubmed: 29915529
pmcid: 5994595
Yu PH (1986) Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent. Res Commun Chem Pathol Pharmacol. 51(2):163–71
pubmed: 3961266
Yui K, Ikemoto S, Ishiguro T, Goto K (2000) Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 914:1–12. https://doi.org/10.1111/j.1749-6632.2000.tb05178.x
doi: 10.1111/j.1749-6632.2000.tb05178.x
pubmed: 11085303
Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM (2018) Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 197(6):788–800. https://doi.org/10.1164/rccm.201705-0943OC
doi: 10.1164/rccm.201705-0943OC
pubmed: 28934596
pmcid: 5855067
Zhang L, Dyer DC (1990) Receptor mechanisms for 5-hydroxytryptamine (5-HT) in isolated ovine umbilical vein. Eur J Pharmacol. 184(2–3):281–93. https://doi.org/10.1016/0014-2999(90)90620-l
doi: 10.1016/0014-2999(90)90620-l
pubmed: 1981873
Zhao SX, Kwong C, Swaminathan A, Gohil A, Crawford MH (2018) Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy. JACC Heart Fail. 6(3):209–218. https://doi.org/10.1016/j.jchf.2017.10.006
doi: 10.1016/j.jchf.2017.10.006
pubmed: 29496022